Key facts
- It has raised $80.4M; the latest was Later Stage VC in Mar 2026.
- Notable investors include GL Ventures, Beijing Ruiyin Weiye Technology Development, HM Capital, HM Venture Partners, Kunnuo Tianqin Venture Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Huidagene Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Huidagene Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Huidagene Therapeutics
Developer of gene therapy drugs designed for the treatments of rare human genetic diseases. The company specializes in the development and production of gene replacement and gene editing therapeutic products based on Adeno-Associated Virus technologies, providing sophisticated and reliable research and solutions for the treatment of various neurodegenerative diseases.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Employees
- 150
- Website
- cn.huidagene.com/
- Ownership
- Privately Held (backing)
Huidagene Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Huidagene Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Huidagene Therapeutics in its N-PORT filings yet. We sweep new filings monthly.